The annual meeting of the American College of Gastroenterology was held from Oct. 25 to 30 in Philadelphia and attracted ...

Roughly half as many patients with cirrhosis in remission from overt hepatic encephalopathy (OHE) experienced a breakthrough ...

For patients with a history of overt hepatic encephalopathy (OHE), rifaximin monotherapy (MT) results in significantly fewer ...

LAVAL, QC / ACCESSWIRE / October 27, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals (“Salix”), announced that results of an ...

(NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced that results of an analysis of Xifaxan® (rifaximin) monotherapy will be presented during a ...

The antibiotic, rifaximin, has enabled the global emergence of vancomycin-resistant enterococcus faecium, or VRE, a superbug that frequently causes serious infections in hospitalised patients ...

The new eight-year study found that the antibiotic rifaximin has led to the global emergence of an almost untreatable form of the AMR superbug vancomycin-resistant enterococcus faecium (VRE), a ...

The new eight-year study found that the antibiotic rifaximin has led to the global emergence of an almost untreatable form of ...

For patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt (TIPS) placement, rifaximin used before and after the procedure is associated with a reduced risk for overt ...

But when exposed to rifaximin, the VRE bacteria don't just get one boost – they gain multiple abilities, like super-speed and super-strength, allowing them to easily defeat even the final boss ...